Daily Administration of Physostigmine Does Not Ameliorate the Spatial Learning Impairments Induced by AF64A

Trey Folkers  
*Illinois Wesleyan University*

James Bedrosian  
*Illinois Wesleyan University*

Wayne Dornan, Faculty Advisor  
*Illinois Wesleyan University*

Follow this and additional works at: [https://digitalcommons.iwu.edu/jwprc](https://digitalcommons.iwu.edu/jwprc)

Folkers, Trey; Bedrosian, James; and Dornan, Faculty Advisor, Wayne, "Daily Administration of Physostigmine Does Not Ameliorate the Spatial Learning Impairments Induced by AF64A" (1996). *John Wesley Powell Student Research Conference*. 27.  

This is protected by copyright and/or related rights. It has been brought to you by Digital Commons @ IWU with permission from the rights-holder(s). You are free to use this material in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself. This material has been accepted for inclusion by faculty at Illinois Wesleyan University. For more information, please contact digitalcommons@iwu.edu.  
©Copyright is owned by the author of this document.
DAILY ADMINISTRATION OF PHYSOSTIGMINE DOES NOT AMELIORATE THE SPATIAL LEARNING IMPAIRMENTS INDUCED BY AF64A

Trey Folkers, James Bedrosian, and Wayne Dornan*,
Department of Psychology, IWU

Alzheimer's Disease (AD) is a progressive degenerative disorder of the brain clinically manifested by cognitive deterioration. It usually begins in later life (> 65 years old), and results in death in about 3 to 10 years. Although originally thought to be a rare disease, AD has now reached startling proportions. It has been estimated that approximately 4 million Americans have AD, 19 million Americans say they have a family member with AD, and 37 million know someone with AD. Although significant progress has been made toward understanding the etiology of AD, presently there is no known cause or treatment. Pathologically AD is characterized by a profound deficiency of the neurotransmitter, acetylcholine. As a result, an intense research effort revolves around palliative strategies using drugs that effect the cholinergic system. Presently, studies using "cholinergic enhancers" have produced the most encouraging results. In another study presented at this conference we found a dramatic impairment in spatial learning in animals treated with the cholinergic neurotoxin, AF64A. In this study we attempt to ameliorate the spatial learning deficits induced by AF64A by using the acetylcholinesterase inhibitor, physostigmine. Our preliminary results indicate that compared to controls, daily treatment of an acetylcholinesterase inhibitor does not improve performance on a spatial learning task in AF64A lesioned animals. The implications of these results for future treatment strategies regarding AD will be discussed at this conference.